# A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

> **NCT07155668** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Viridian Therapeutics, Inc.** · enrollment: 87 (actual)

## Conditions studied

- Thyroid Eye Disease

## Interventions

- **DRUG:** VRDN-003
- **DEVICE:** Autoinjector

## Key facts

- **NCT ID:** NCT07155668
- **Lead sponsor:** Viridian Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2026-07
- **Final completion:** 2026-11
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07155668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07155668, "A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT07155668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*